William M. Mihalko, M.D., Ph.D.

Myoscience, Inc., a medical device company dedicated to relieving pain through targeted therapies, today announced clinical trial results demonstrating that iovera° therapy significantly reduced the use of opioids following total knee arthroplasty (TKA) surgery (primary endpoint) and significantly reduced pain in a prospective, randomized study. Preliminary results will be presented tomorrow in the Innovation Theater at the 2019 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in Las Vegas by lead investigator William Mihalko, M.D., Ph.D., orthopedic surgeon at Campbell Clinic Orthopaedics in Memphis, Tenn.

Myoscience’s FDA-cleared platform technology, the iovera° system, uses cryoneurolysis to freeze nerves in the knee to deliver fast and immediate opioid-free pain relief with results that are sustained for up to 90 days. 1 During the simple outpatient procedure, iovera° safely and effectively allows patients with knee pain to leave their physician’s office experiencing less pain than they had when they walked in… Continue reading.

Myoscience, Inc. announced today that it has completed enrollment in its randomized, controlled trial at the Campbell Clinic in Memphis, Tennessee. This study enrolled 125 patients and compares the effect of cryoanalgesia using the iovera° system to the standard of care for managing pain after total knee replacement surgery (TKA).

The Myoscience iovera° system is currently being used to treat chronic and perioperative knee pain. The Campbell Clinic study will demonstrate how cryoanalgesia can significantly reduce opioid consumption after TKA, and lead to improved physical function and enhanced recovery. Analysis of interim data confirms that cryoanalgesia with the iovera° system can be a preferred treatment for relieving postoperative TKA pain.

“I am very impressed with the results of this prospective randomized study thus far. The positive effect of the iovera° system has exceeded our original expectations”, stated Dr. William Mihalko, MD, Principal Investigator for this study. “Having a technology as effective as this to combat excessive opioid use after primary TKA can be a game changer for many patients. Many of us will adopt the use of the technology on a regular basis at my institution,” he added… Continue reading.